4D Molecular Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
FDMT Nasdaq 2830 www.4dmoleculartherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for 4D Molecular Therapeutics, Inc.

4DMT to Participate in Upcoming Investor Conferences - Aug 25th, 2026 6:00 am
OCUL, FDMT Stock Clock Best Day In Weeks After EyePoint’s Trial Setback — Here’s Why - Aug 17th, 2026 5:51 pm
4DMT Announces New Employment Inducement Grants - Aug 14th, 2026 2:05 pm
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates - Aug 13th, 2026 4:05 pm
4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones - Aug 13th, 2026 2:05 pm
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates - Aug 13th, 2026 6:15 am
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates - Aug 6th, 2026 7:50 am
Bioventus (BVS) Q2 Earnings Meet Estimates - Aug 5th, 2026 7:00 am
Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls - Jul 31st, 2026 7:46 am
Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates - Jul 30th, 2026 5:20 am
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population - Jul 18th, 2026 1:15 pm
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists - Jun 30th, 2026 2:05 pm
4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital - Jun 29th, 2026 6:00 am
4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD - Jun 29th, 2026 6:00 am
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker - Jun 26th, 2026 5:30 am
Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength? - Jun 23rd, 2026 7:42 am
Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight - May 27th, 2026 6:31 am